Pfizer Reports Strong Q1 Operational Revenue Growth (Ex-COVID), Advances Strategic Pipeline, and Resolves Key Legal Matters
PFE sits 21% above its 52-week low of $21.97.
Summary
Pfizer reported Q1 2026 revenues of $14.5 billion, a 5% increase year-over-year, driven by 7% operational growth excluding COVID-19 products. The company continues its strategic restructuring, advances its pipeline with new approvals and filings, and resolves significant legal proceedings, while also noting new tariff risks.
Key Events · Earnings and Guidance · PFE
-
Q1 Financial Performance
Total revenues increased 5% to $14.5 billion in Q1 2026, compared to $13.7 billion in Q1 2025. Excluding contributions from Comirnaty and Paxlovid, total revenues increased 7% operationally. Diluted EPS decreased to $0.47 from $0.52 year-over-year.
-
Strategic Portfolio Shift
Strong operational growth was observed in key products including Padcev (+39%), Nurtec ODT/Vydura (+41%), Lorbrena (+32%), Abrysvo (+31%), Orgovyx (+43%), and Oncology biosimilars (+55%). This growth significantly offset declines in COVID-19 product revenues from Comirnaty (-59%) and Paxlovid (-63%).
-
Cost Realignment and Synergies
Multi-year cost realignment programs are progressing, with $4.3 billion incurred to date out of an expected $5.3 billion total, aiming for $5.7 billion in net cost savings through 2026. The Manufacturing Optimization Program has incurred $1.1 billion out of $1.4 billion, targeting $1.5 billion in net cost savings by 2027. Additionally, $600 million in annual cost synergies are expected from the Metsera acquisition by the end of 2026.
-
Business Development Updates
Pfizer completed the exit of its 11.7% investment in ViiV on March 31, 2026, receiving $1.875 billion in cash proceeds. The company also detailed its November 2025 acquisition of Metsera for $8.0 billion (including $2.3 billion in potential contingent value rights) and a February 2026 in-licensing arrangement with Sciwind Biosciences for up to $495 million for a GLP-1 receptor agonist in China.
Analysis · PFE · Life Sciences
Pfizer's Q1 2026 report highlights a successful strategic pivot away from its COVID-19 product dependency, demonstrating robust operational growth in its core biopharmaceutical portfolio. While overall diluted EPS saw a slight decline year-over-year, the underlying strength in new and established non-COVID products, coupled with significant cost-saving initiatives and strategic acquisitions, positions the company for future growth. The resolution of several long-standing legal matters reduces uncertainty, though new tariff risks on patented pharmaceuticals bear close monitoring.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PFE was trading at $26.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $149.6B. The 52-week trading range was $21.97 to $28.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.